Metabolic Profiling of Obesity With And Without The Metabolic Syndrome: A Multi-Sample EvaluationShow others and affiliations
2022 (English)In: Journal of Clinical Endocrinology and Metabolism, ISSN 0021-972X, E-ISSN 1945-7197, Vol. 107, no 5, p. 1337-1345Article in journal (Refereed) Published
Abstract [en]
CONTEXT: There is a dispute whether obesity without major metabolic derangements may represent a benign condition or not.
OBJECTIVE: We aimed to compare the plasma metabolome in obese subjects without the metabolic syndrome (MetS) to normal-weight subjects without MetS, as well as to obese subjects with MetS.
DESIGN: Cross-sectional.
SETTING: Two academic centers in Sweden.
PARTICIPANTS: Three population-based samples (EpiHealth, n=2342, SCAPIS-Uppsala, n=4985 and SCAPIS-Malmö, n=3978) in which individuals were divided into groups according to their BMI and presence/absence of MetS (NCEP/consensus criteria).
INTERVENTION: None.
MAIN OUTCOME MEASURE: 791 annotated endogenous metabolites measured by ultra-performance liquid chromatography tandem mass spectrometry.
RESULTS: We observed major differences in metabolite profiles (427 metabolites) between obese (BMI ≥ 30 kg/m 2) and normal-weight (BMI < 25 kg/m 2) subjects without MetS after adjustment for major life-style factors. Pathway enrichment analysis highlighted branch-chained and aromatic amino acid synthesis/metabolism, aminoacyl-tRNA biosynthesis and sphingolipid metabolism. The same pathways, and similar metabolites, were also highlighted when obese subjects with and without MetS were compared despite adjustment for BMI and waist circumference, or when the metabolites were related to BMI and number of MetS components in a continuous fashion. Similar metabolites and pathways were also related to insulin sensitivity (Matsuda index) in a separate study (POEM, n=501).
CONCLUSION: Our data suggest a graded derangement of the circulating metabolite profile from lean to obese to the metabolic syndrome, in particular for metabolites involved in amino acid synthesis/metabolism and sphingolipid metabolism. Insulin resistance is a plausible mediator of this gradual metabolic deterioration.
Place, publisher, year, edition, pages
Oxford University Press, 2022. Vol. 107, no 5, p. 1337-1345
Keywords [en]
Epidemiology, insulin resistance, metabolic syndrome, metabolomics, obesity
National Category
Endocrinology and Diabetes
Identifiers
URN: urn:nbn:se:oru:diva-96288DOI: 10.1210/clinem/dgab922ISI: 000783663300013PubMedID: 34984454Scopus ID: 2-s2.0-85130013765OAI: oai:DiVA.org:oru-96288DiVA, id: diva2:1626936
Funder
Swedish Heart Lung Foundation, 2019-0526 20200173Swedish Research Council, 2019-01236 349-2006237EU, European Research Council, ERC-STG-2015-679242Knut and Alice Wallenberg FoundationSwedish Foundation for Strategic Research , IRC150067
Note
Funding agencies:
Skåne University Hospital
Strategic Research Area Exodiab 2009-1039
Lund University Diabetes Center
2022-01-122022-01-122023-12-08Bibliographically approved